In an Aug. 29 statement,the Canonsburg, Pa.-based drugmaker said it expected to launch its generic EpiPen “in several weeks.” However, the launch has been delayed by several months.
“We expect to launch this year once we have assured that sufficient inventory will be available to meet anticipated orders, created the necessary packaging for the product and created the necessary labeling for the product,” Mylan spokeswoman Nina Devlin told Bloomberg Monday in an email. “We are diligently working to complete these efforts in order to provide the generic as soon as possible.”
Mylan announced plans to launch a generic EpiPen in late August in response to heated scrutiny over the cost of EpiPens, which has increased by more than 400 percent since 2007. A two-pack of EpiPens has a list price of $608. The generic version will cost $300 for a pack of two.
More articles on supply chain:
FDA approves Teva’s generic HIV drug
5 factors driving supply chain innovation
Hospital bed company LINET buys majority stake in BORCAD Medical
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
